©The Author(s) 2022.
World J Gastrointest Endosc. Mar 16, 2022; 14(3): 153-162
Published online Mar 16, 2022. doi: 10.4253/wjge.v14.i3.153
Published online Mar 16, 2022. doi: 10.4253/wjge.v14.i3.153
Table 2 Survey responses of 103 inflammatory bowel disease patients
| Survey answers | ||||||
| Close contacts with positive patients (n, %) | Yes | 17, 16.5 | ||||
| No | 85, 82.5 | |||||
| Nd | 1, 1 | |||||
| Tested for swab (n, %) | Yes | 13, 12.5 | Positive | 1, 1 | ||
| Negative | 12, 11.5 | |||||
| No | 90, 87.5 | |||||
| Symptoms (n, %) | No symptoms | 49, 47.5 | ||||
| Mild | Cough | 19, 18.4 | ||||
| Changes in taste/smell | 6, 5.8 | |||||
| Muscle and joint pain | 12, 11.6 | |||||
| Asthenia | 11, 10.6 | |||||
| Fever | 18, 17.4 | |||||
| GI symptoms | 23, 22.3 | |||||
| Severe | Mild dyspnea | 4, 3.8 | ||||
| Pneumonia | 1, 0.9 | |||||
| Total number of patients (n) | 103 | |||||
- Citation: Conti CB, Mainardi E, Soro S, Testa S, De Silvestri A, Drago A, Cereatti F, Grassia R. SARS-CoV-2 in inflammatory bowel disease population: Antibodies, disease and correlation with therapy. World J Gastrointest Endosc 2022; 14(3): 153-162
- URL: https://www.wjgnet.com/1948-5190/full/v14/i3/153.htm
- DOI: https://dx.doi.org/10.4253/wjge.v14.i3.153